3 Houston innovators to know this week

who's who

This week's innovators to know in Houston includes Marcelo Cordini of December Labs, Courtney Sikes Longmore of Pure Palate, and Josh Ruben of Z3VR. Photos courtesy

Editor's note: In today's Monday roundup of Houston innovators, I'm introducing you to three innovators representing a diverse set of industries — from virtual reality to software development — all making headlines in Houston this week.

Marcelo Cordini, co-founder of December Labs

Marcelo Cordini, co-founder of December Labs, joins the Houston Innovators Podcast to discuss the unique service his company provides an evolving tech workforce. Photo courtesy of December Labs

Marcelo Cordini realized that nowadays, software developers are like rockstars. They can make or break a startup or technology's success and finding the best development team can be hard to do. But hiring and cultivating software talent is a specialty most companies — big or small — has the time or expertise to handle. That's where December Labs comes in.

"We are always learning new technologies — that's our focus," Cordini says. "If you have a big company focused on real estate, your focus is on real estate — not technology. So, if you partner with a company like us, it will give you that value to have someone who knows how to hire developers and how to train them."

Cordini joined the Houston Innovators Podcast last week to discuss the unique service his company provides and the state of software employment is in these days. Read more and stream the episode.

Courtney Sikes Longmore, founder at Pure Palate

Women in the work place have been hit the hardest by the pandemic. Photo via Pexels

According to Labor Department statistics, 1.1 million people left the workforce in August and September, and of that 800,000 were women. This data wasn't surprising to Courtney Sikes Longmore, an entrepreneur and founder of Pure Palate — however it was a call to action. She teamed up with Sesh Coworking to host a panel (click here to stream) to discuss how COVID-19 has disproportionately affected women and co-wrote a guest article with Maggie Segrich on the subject too.

"A decline of women in the labor force, on teams, in leadership positions and in decision-making roles compromises not just our economy's recovery and productivity, but also the innovation and effectiveness in industry, competitiveness on a global scale, aspirations of future generations of women, and society as a whole," they write. Read more.

Josh Ruben, CEO of Z3VR

Houston-based Z3VR has been granted $500,000 to work or virtual reality applications in space. Photo courtesy of Z3VR

The Houston-based Translational Research Institute for Space Health is always trying to find and support innovations that will help current and future astronauts, and Josh Ruben's company, Z3VR, was a perfect fit to work on virtual reality applications in space. The company received a $500,000 grant from TRISH last month to continue exploring how the wide world of virtual reality can boost mental and physical health for astronauts on a mission to Mars.

"This TRISH funding means the world," he says. "Not only do we have these partnerships within NASA, which we expect will really help address these problems, but we are already taking the funds and putting them to work in the US health care system." Read more.

Marcelo Cordini, co-founder of December Labs, joins the Houston Innovators Podcast to discuss the unique service his company provides an evolving tech workforce. Photo courtesy of December Labs

Houston company is connecting rockstar developers with growing startups and big corporations

HOUSTON INNOVATORS PODCAST EPISODE 53

For tech startups, a great business idea is step one, design and development is that next, make-or-break step. A Houston company exists to help staff development teams with talented specialists across various fields.

December Labs, which has offices in Uruguay and Houston, has seen the industry evolve since its founding in 2014. Nowadays, it's a competition for startups and corporations alike to get the best tech teams.

"Developers are kind of rockstars nowadays — it's very hard to attract them and keep them happy. We can help with that," says Marcelo Cordini, co-founder of December Labs, on this week's episode of the Houston Innovators Podcast.

Cordini and his co-founders — Martin Palatnik, Diego San Esteban, and Washington Miranda — designed their business's service to provide development teams to companies of all sizes and industries, from startups to big companies.

"We are always learning new technologies — that's our focus," Cordini says. "If you have a big company focused on real estate, your focus is on real estate — not technology. So, if you partner with a company like us, it will give you that value to have someone who knows how to hire developers and how to train them."

Similar to most companies, the pandemic posed its challenges to December Labs, but one thing that the company has going for it is the evolution of the workforce. Now, it's way less important to have your team in house, as Cordini explains.

"It's the same to have your developers in South America as having them in the U.S., right? Because we are all working from home," he says. "We were lucky and prepared [for the pandemic]."

You can listen to the full interview with Cordini below — or wherever you stream your podcasts — and subscribe for weekly episodes.

When Marcelo Cordini moved his company to Houston, he didn't know what to expect. Now, a couple years later, he's poised for growth. Courtesy of December Labs

Growing UX developer credits Houston with company success

UX expectations

In December 2014, four guys from Uruguay banded together and created December Labs, a company specializing in UX and UI design, web development and mobile development for startups. After three years of success there, co-founder Marcelo Cordini's wife had her job transferred to "a city full of companies from everywhere" — Houston.

"To be honest, I came without expectations, not knowing what to do with the tech space here," Cordini says. "But I discovered that the city's innovation scene was rising and that the whole startup environment too. We didn't know Houston had a startup environment."

Cordini, along with co-founders, Martin Palatnik, Diego San Esteban, and Washington Miranda, have created a base here in Houston at Station Houston, with headquarters stationed in San Francisco as well as Uruguay.

The company's international presence can be seen in their client base, which includes industry giants like Google, Accenture, and Nest.

"When I got here, people told us that we should just go to Austin," Cordini says. "But, to be honest, this is a big city with lots of great companies — not just corporations, but startups — that are growing and thrive and have good connections. So, maybe you don't hear much about the startup world outside the U.S., but I think the startups right now are at a different level here."

December Labs has started working with local startups around the city and has grown to have around 15 engineers and designers working for the company.

Cordini says that their experience working at Station Houston has really broadened their horizons and allowed them to make connections that they wouldn't have made otherwise.

"It's great to have connections, and that's something that I love here in Houston," Cordini says. "People are willing to help each other."

A main goal for December Labs is to help other companies succeed through their mission-driven, people-focused work. But they're focused on the future.

"We've been growing like crazy over the past year," Cordini says. "We would love to keep growing here in Houston by getting more clients and helping more startups and corporations. Our idea is to continue our expansion here in Houston and all around Texas, for sure."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice team keeps CO2-to-fuel devices running 50 times longer in new study

Bubbling Up

In a new study published in the journal Science, a team of Rice University researchers shared findings on how acid bubbles can improve the stability of electrochemical devices that convert carbon dioxide into useful fuels and chemicals.

The team led by Rice associate professor Hoatian Wang addressed an issue in the performance and stability of CO2 reduction systems. The gas flow channels in the systems often clog due to salt buildup, reducing efficiency and causing the devices to fail prematurely after about 80 hours of operation.

“Salt precipitation blocks CO2 transport and floods the gas diffusion electrode, which leads to performance failure,” Wang said in a news release. “This typically happens within a few hundred hours, which is far from commercial viability.”

By using an acid-humidified CO2 technique, the team was able to extend the operational life of a CO2 reduction system more than 50-fold, demonstrating more than 4,500 hours of stable operation in a scaled-up reactor.

The Rice team made a simple swap with a significant impact. Instead of using water to humidify the CO2 gas input into the reactor, the team bubbled the gas through an acid solution such as hydrochloric, formic or acetic acid. This process made more soluble salt formations that did not crystallize or block the channels.

The process has major implications for an emerging green technology known as electrochemical CO2 reduction, or CO2RR, that transforms climate-warming CO2 into products like carbon monoxide, ethylene, or alcohols. The products can be further refined into fuels or feedstocks.

“Using the traditional method of water-humidified CO2 could lead to salt formation in the cathode gas flow channels,” Shaoyun Hao, postdoctoral research associate in chemical and biomolecular engineering at Rice and co-first author, explained in the news release. “We hypothesized — and confirmed — that acid vapor could dissolve the salt and convert the low solubility KHCO3 into salt with higher solubility, thus shifting the solubility balance just enough to avoid clogging without affecting catalyst performance.”

The Rice team believes the work can lead to more scalable CO2 electrolyzers, which is vital if the technology is to be deployed at industrial scales as part of carbon capture and utilization strategies. Since the approach itself is relatively simple, it could lead to a more cost-effective and efficient solution. It also worked well with multiple catalyst types, including zinc oxide, copper oxide and bismuth oxide, which are allo used to target different CO2RR products.

“Our method addresses a long-standing obstacle with a low-cost, easily implementable solution,” Ahmad Elgazzar, co-first author and graduate student in chemical and biomolecular engineering at Rice, added in the release. “It’s a step toward making carbon utilization technologies more commercially viable and more sustainable.”

A team led by Wang and in collaboration with researchers from the University of Houston also recently shared findings on salt precipitation buildup and CO2RR in a recent edition of the journal Nature Energy.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings